What is the phentermine for weight loss

Therapy for obesity: Phentermine plus topiramate tested in phase III

Excessive obesity is associated with increased mortality. Whether a combination of the amphetamine derivative phentermine and topiramate, which is approved for the treatment of epilepsy and for migraine prophylaxis, can be used to achieve weight loss was determined in a randomized phase III study in 2,487 patients (70% women) with a body mass -Index (BMI) between 27 and 45 and at least two comorbidities (hypertension, dyslipidemia, diabetes or prediabetes, abdominal obesity) checked. In addition to diet and lifestyle advice, the patients received either a combination preparation of 7.5 mg phentermine and 46 mg topiramate with controlled release (n = 498) or in double dose (n = 995) or placebo (n = 994).

After 56 weeks there was an average weight reduction of 1.4 kg with placebo (–1.2%, 95% CI –1.8 to –0.7). Patients taking phentermine / topiramate at low doses lost an average of 8.1 kg (-7.8%, CI -8.5 to -7.1, p< 0,0001), unter="" der="" höheren="" dosierung="" 10,2 kg="" (–9,8 %,="" ki="" –10,4="" bis="" –9,3;="">< 0,0001). bei="" 21 %="" der="" patienten="" unter="" placebo="" reduzierte="" sich="" das="" gewicht="" um="" mindestens="" 5="" %.="" unter="" der="" niedrig="" dosierten="" prüfmedikation="" war="" dies="" bei="" 62 %="" der="" fall="" und="" in="" der="" gruppe="" mit="" hochdosierter="" medikation="" bei="" 70 %="" der="" patienten.="" der="" unterschied="" war="" mit="" jeweils="">< 0,0001 statistisch="" signifikant.="" für="" eine="" mehr="" als="" zehnprozentige="" reduktion="" lagen="" die="" vergleichszahlen="" bei="" 7 %,="" 37 %="" und="" 48 %,="" ebenfalls="" mit="" signifikanter="" überlegenheit="" in="" den="" verumgruppen="">< 0,0001). neben="" mundtrockenheit="" (13="" und="" 21 %),="" parästhesien="" (14 und="" 21 %),="" obstipation="" (15="" und="" 17 %)="" sowie="" schlafstörungen="" (6="" und="" 10 %)="" traten="" als="" nebenwirkungen="" schwindel="" (7="" und="" 10 %)="" und="" geschmacksstörungen="" (7="" und="" 10 %)="" auf.="" 4="" %="" der="" patienten="" unter="" placebo="" und="" niedriger="" verumdosis="" entwickelten="" depressive="" symptome,="" 7 %="" unter="" höherer="" verumdosis.="" 3,="" 5="" und="" 8 %="" in="" den="" jeweiligen="" gruppen="" bekamen="">

Conclusion: With the combination of phentermine and topiramate, weight loss can be supported with medication for very overweight people. This is a relevant finding, especially since after the withdrawal of rimonabant and sibutramine from the market, the options for pharmacological therapy of obesity are limited. At the same time, the study provides indications of a positive influence of the medication or weight loss on other cardiovascular risk factors. However, more psychiatric reactions occurred, especially with higher doses of verum medication. Based on the experience with rimonabant and sibutramine, further data on the long-term safety of the medication are therefore desirable. Christine Vetter

Gadde KM et al .: Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial. Lancet 2011, DOI: 10.1016 / S0140-6736 (11) 60205-5. MEDLINE